- Home
- ARMP vs RCKT Comparison
ARMP vs RCKT Comparison
Compare ARMP & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARMP | RCKT |
|---|---|---|
| Founded | N/A | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 199.7M | 239.3M |
| IPO Year | 1996 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ARMP | RCKT |
|---|---|---|
| Price | $3.66 | $2.27 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 14 |
| Target Price | ★ $17.50 | $8.58 |
| AVG Volume (30 Days) | 96.2K | ★ 2.2M |
| Earning Date | 11-11-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.37 |
| EPS | N/A | ★ 0.66 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $915.60 |
| P/E Ratio | ★ N/A | $3.50 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.75 | $2.17 |
| 52 Week High | $14.98 | $5.45 |
Technical Indicators
Market Signals| Indicator | ARMP | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 49.63 | 37.77 |
| Support Level | $3.38 | N/A |
| Resistance Level | $4.07 | $3.70 |
| Average True Range (ATR) | 0.36 | 0.18 |
| MACD | 0.07 | 0.02 |
| Stochastic Oscillator | 69.06 | 18.70 |
Price Performance
Historical ComparisonAbout ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.